Mr. Bill Adams reports

NERVGEN PHARMA APPOINTS ADAM ROGERS AS CHIEF EXECUTIVE OFFICER TO CONTINUE LEADING THE COMPANY'S GROWTH AND EXECUTION OF ITS MISSION IN SPINAL CORD INJURY

Nervgen Pharma Corp.'s board of directors has unanimously appointed Dr. Adam Rogers, MD, as president and chief executive officer, effective immediately. Dr. Rogers will continue leading the company's growth and execution of its mission to transform the lives of individuals living with spinal cord injury.

The board's decision reflects its confidence in Dr. Rogers's leadership, demonstrated through decisive execution against key milestones during his tenure as interim CEO, including the company's recent Nasdaq listing. Under his leadership, Nervgen has established itself as a leader in the development of neuroreparative therapeutics and positioned NVG-291 for late-stage development and commercialization.

"Following a thorough evaluation during Adam's tenure as interim CEO, the board concluded that his leadership has been defined by results," said Craig Thompson, independent director and member of the nominating and corporate governance committee. "Adam exemplifies the leadership qualities that Nervgen requires, bringing the unique perspective of a practising physician and seasoned biotech executive who understands the complexities and discipline inherent in advancing a novel therapy such as NVG-291. His leadership reflects a commitment to all stakeholders from patients, families and advocates to shareholders and employees, aligned around the shared objective of bringing NVG-291 to market as the first approved pharmacologic treatment for spinal cord injury."

"My role as CEO represents a mission-driven commitment to execution and to the individuals, families and communities who are counting on us to achieve meaningful progress," said Dr. Rogers. "We are at a point in the company's growth where focus, discipline and execution matter more than ever, and, as both a physician and biotech executive, I understand the promise of NVG-291 and the responsibility that comes with leading it forward.

"That responsibility is deeply personal to me," continued Dr. Rogers. "Reflecting both the long-term investments I have made in this company and my desire to continue to achieve what was once thought impossible: meaningful recovery and renewed independence even years after a spinal cord injury. I am honoured to continue leading Nervgen forward with the urgency and discipline this moment demands and that this company and the communities we fight for deserve."

In connection with Dr. Rogers's appointment, the company granted an aggregate of 717,891 stock options. The options vest over a four-year period, with 25 per cent vesting on the first anniversary of the grant date and the remaining 75 per cent vesting in equal monthly instalments over the subsequent 36 months, subject to continued service. Of the options granted, 614,799 are exercisable at $5.06 (U.S.) per share for a period of 10 years from the date of grant, and 103,092 are exercisable at $5.57 (U.S.) per share for a period of five years from the date of grant. All equity awards are subject to the terms and conditions of the company's existing option plan and the policies of the TSX Venture Exchange.

About Dr. Adam Rogers, MD

Dr. Rogers has served on Nervgen's board of directors since July, 2022, and was appointed chairman and interim chief executive officer in July, 2025, as part of a leadership transition supporting the company's next stage of growth. Dr. Rogers is a principal of Boston-based PFP Biosciences Holdings and a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous.

Dr. Rogers previously co-founded Hemera Biosciences, a clinical-stage biotechnology company developing a one-time investigational gene therapy administered as an outpatient intravitreal injection to preserve vision in patients with geographic atrophy. Dr. Rogers served as chief executive officer from 2017 until December, 2020, when the rights to its lead program were acquired by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Earlier in his career, Dr. Rogers served as an assistant professor of ophthalmology at the New England Eye Center of Tufts Medical Center. He has written numerous peer-reviewed publications and holds an MD from Emory University school of medicine.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. Nervgen's lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the phase 1b/2a Connect SCI study in individuals with chronic SCI between one and 10 years postinjury, and is the first pharmacologic candidate to demonstrate durable improvement in function, independence and quality of life. The company's phase 1b/2a Connect SCI study in individuals with subacute SCI is continuing, alongside preparation for a phase 3 clinical trial in chronic SCI. NVG-291 has received fast-track designation from the Food and Drug Administration and orphan drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the company's next-generation candidate, NVG-300, Nervgen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.

We seek Safe Harbor.